Maragogipe (Coffea arabica)

Maragogipe (Coffea arabica) is a large-bean arabica coffee cultivar originating from Maragogipe, Brazil, prized for its mild, nuanced cup profile. Like all arabica coffee, it contains caffeine and chlorogenic acids as its primary bioactive compounds, which influence adenosine receptor signaling and antioxidant activity.

Origin & History

Maragogipe is a natural mutation of Coffea arabica Typica discovered in 1870 near Maragogipe, Brazil, characterized by exceptionally large coffee beans, leaves, and internodes due to a single dominant gene. This cultivar is grown at high altitudes in select regions including Brazil, Guatemala, Nicaragua, and El Salvador, where it produces distinctive large beans prized for their unique flavor profile.

Historical & Cultural Context

Discovered as a spontaneous mutation in Maragogipe, Bahia, Brazil in 1870, this coffee variety has been cultivated for over 150 years primarily for its distinctive large beans and unique cup characteristics. Historical use is limited to beverage preparation rather than medicinal applications.

Health Benefits

• No clinical health benefits documented - research dossier contains only agricultural and culinary information
• No biomedical studies available - existing data focuses on cultivation practices and flavor profiles
• No evidence of therapeutic effects - sources describe only coffee variety characteristics
• No safety or efficacy data - research limited to agronomic traits
• No pharmacological properties studied - documentation addresses only bean size and growing conditions

How It Works

Caffeine, present in Maragogipe beans as in all Coffea arabica varieties, acts as a competitive antagonist at adenosine A1 and A2A receptors, reducing fatigue signaling and increasing dopamine and norepinephrine release. Chlorogenic acids, particularly 5-caffeoylquinic acid, inhibit glucose-6-phosphatase activity and modulate Nrf2-mediated antioxidant pathways. These mechanisms are shared across arabica cultivars and are not specifically documented for the Maragogipe variety in isolation.

Scientific Research

No clinical trials, meta-analyses, or biomedical studies were found in the research dossier. The available information pertains exclusively to agricultural characteristics, cultivation methods, and sensory profiles of this coffee cultivar.

Clinical Summary

No clinical trials have been conducted specifically on the Maragogipe cultivar as a supplement or therapeutic agent. Available evidence for its bioactive compounds, caffeine and chlorogenic acids, derives from studies on Coffea arabica broadly; these cannot be attributed specifically to Maragogipe due to varietal differences in bean composition. The existing research dossier for this cultivar contains only agricultural, horticultural, and sensory data. Any health-related claims for Maragogipe specifically are unsupported by current biomedical literature.

Nutritional Profile

Maragogipe (Coffea arabica) is a large-bean Arabica cultivar ('elephant bean') whose nutritional composition closely mirrors standard Arabica coffee. Per 240 mL brewed cup (approximately 8 oz, using ~10 g ground coffee): Calories: 2–5 kcal; Total carbohydrates: 0–1 g; Protein: 0.3 g; Fat: 0 g; Fiber: 0 g (insoluble fiber remains in grounds). Key bioactive compounds: Caffeine: 80–120 mg per cup (generally lower than Robusta; Maragogipe's larger bean size and lower bean density may yield slightly milder caffeine concentration per gram compared to compact Arabica varieties); Chlorogenic acids (CGAs): 70–200 mg per cup, primarily 5-caffeoylquinic acid — CGAs are the dominant antioxidant polyphenols in Arabica coffee and are partially degraded during roasting (light roast retains more); Trigonelline: 50–100 mg per cup, a niacin precursor that degrades to niacin (vitamin B3) during roasting; Niacin (B3): approximately 0.5–1.0 mg per cup post-roasting from trigonelline conversion; Diterpenes (cafestol and kahweol): present primarily in unfiltered preparations (e.g., French press), 0.2–4 mg per cup depending on brew method — largely absent in paper-filtered coffee; Potassium: 116 mg per cup; Magnesium: 7 mg per cup; Phosphorus: 7 mg per cup; Riboflavin (B2): 0.18 mg per cup. Maragogipe-specific notes: The cultivar's exceptionally large bean size (roughly 2–3x standard Arabica bean volume) results from cell expansion rather than proportionally increased dry matter density, meaning per-gram composition is comparable to other Arabica types rather than substantially different. Its thin cell walls and low density contribute to a mild, low-acidity flavor profile. Bioavailability: CGAs have moderate bioavailability (33–67%); cafestol/kahweol are lipid-soluble and bioavailable only in unfiltered brews; caffeine is nearly 100% bioavailable orally. No cultivar-specific nutritional studies exist; values are extrapolated from Arabica coffee compositional literature.

Preparation & Dosage

No clinical dosage information available as Maragogipe has not been studied as a biomedical supplement. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Not applicable - no biomedical synergies studied

Safety & Interactions

As a Coffea arabica cultivar, Maragogipe coffee shares the general safety profile of arabica coffee, with caffeine content posing risks of insomnia, elevated heart rate, and anxiety at high intake. Caffeine interacts with adenosine-based medications, certain antidepressants such as MAOIs, and anticoagulants including warfarin by altering their metabolism via CYP1A2 enzyme pathways. Pregnant individuals are advised to limit total caffeine intake to under 200 mg per day per major obstetric guidelines, and those with hypertension or arrhythmias should use caution. No cultivar-specific contraindications for Maragogipe have been identified in the scientific literature.